Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 1
1 (50.0%)Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Uveal MelanomaUveal Melanoma, MetastaticEye CancerUveal Melanoma, RecurrentEye Cancer, Intraocular Melanoma
- Interventions
- Drug: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Novelwise Pharmaceutical Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT07136181
NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Phase 1
Recruiting
- Conditions
- Malignant Neoplasm of BrainMalignant Neoplasm
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novelwise Pharmaceutical Corporation
- Target Recruit Count
- 79
- Registration Number
- NCT06012695
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung City, Taiwan
News
No news found